Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Between Scylla and Charybdis: antithrombotic therapy in hematopoietic progenitor cell transplant patients

Bone Marrow Transplantation volume 47, pages 1269–1273 (2012)Cite this article

Subjects

Abstract

Patients who undergo hematopoietic progenitor cell transplant may require antithrombotic therapy for a variety of reasons—history of vascular events or developing new ones during therapy. For patients with arterial disease, use of antiplatelet therapy is based on acuity. For primary prevention of an arterial event, aspirin can be withheld at the start of transplant. On the other hand, in the face of a patient experiencing an acute myocardial infarction, aspirin should be given, no matter what the degree of thrombocytopenia is. Patients with cardiac ‘hardware’—stents and mechanical valves—pose difficult issues because as higher risk patients (especially patients with recent implantation of a drug eluting stent) they require more aggressive anticoagulation, even in the face of severe thrombocytopenia. Anticoagulation with heparin is dependent on the platelet count with full dose recommended for a platelet count over 50 × 109/L and prophylactic dosing with platelets in the 20–50 × 109/L range. If the patient develops a distal venous thrombosis, then simple observation can be used, but more proximal thrombosis or pulmonary embolism requires consideration of anticoagulation. Central venous catheter thrombosis is best treated by line removal, as the risk of bleeding is high if the device is left in. The advent of new anticoagulants with minimal drug and food interactions may offer better choices for therapy for these difficult patients. This is also an area in which clinical trials would be helpful to clarify the treatment choices.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Centers for Disease Control and Prevention (CDC). Prevalence of heart disease--United States, 2005. MMWR Morb Mortal Wkly Rep 2007; 56: 113–118.

    Google Scholar 

  2. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–1860.

    Article  Google Scholar 

  3. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy--I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106.

    Article  Google Scholar 

  4. Ciavarella D, Reed RL, Counts RB, Baron L, Pavlin E, Heimbach DM et al. Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. Br J Haematol 1987; 67: 365–368.

    Article  CAS  Google Scholar 

  5. Grines CL, Bonow RO, Casey Jr DE, Gardner TJ, Lockhart PB, Moliterno DJ et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007; 115: 813–818.

    Article  Google Scholar 

  6. Becker RC, Meade TW, Berger PB, Ezekowitz M, O’Connor CM, Vorchheimer DA et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 776S–814S.

    Article  CAS  Google Scholar 

  7. Gaydos LA, Freireich EJ, MANTEL N . The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962; 266: 905–909.

    Article  CAS  Google Scholar 

  8. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G . Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160S–198S.

    Article  CAS  Google Scholar 

  9. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI . Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 141S–159S.

    Article  CAS  Google Scholar 

  10. Falanga A, Marchetti M . Venous thromboembolism in the hematologic malignancies. J Clin Oncol 2009; 27: 4848–4857.

    Article  CAS  Google Scholar 

  11. Ibrahim RB, Peres E, Dansey R, Abidi MH, Abella EM, Gumma MM et al. Safety of low-dose low-molecular-weight-heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literature. Bone Marrow Transplant 2005; 35: 1071–1077.

    Article  CAS  Google Scholar 

  12. Ragni MV, Bontempo FA, Myers DJ, Kiss JE, Oral A . Hemorrhagic sequelae of immune thrombocytopenic purpura in human immunodeficiency virus-infected hemophiliacs. Blood 1990; 75: 1267–1272.

    CAS  PubMed  Google Scholar 

  13. DeLoughery TG . Practical aspects of the oral new anticoagulants. Am J Hematol 2011; 86: 586–590.

    Article  CAS  Google Scholar 

  14. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 2001; 285: 2370–2375.

    Article  CAS  Google Scholar 

  15. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ . Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA 2001; 285: 2864–2870.

    Article  CAS  Google Scholar 

  16. Sun JC, Davidson MJ, Lamy A, Eikelboom JW . Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet 2009; 374: 565–576.

    Article  Google Scholar 

  17. Salem DN, O’Gara PT, Madias C, Pauker SG . Valvular and structural heart disease: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 593S–629S.

    Article  Google Scholar 

  18. DeLoughery TG . Anticoagulation in patients with atrial fibrillation and prosthetic cardiac valves. In: Kitchens, CS, Alving, BM, Kessler, CM (eds). Consultative Hemostasis and Thrombosis. Kitchens, Consultative Thrombosis and Hemostatis: Saunders, 2007, pp 737–746.

    Chapter  Google Scholar 

  19. Cortelezzi A, Moia M, Falanga A, Pogliani EM, Agnelli G, Bonizzoni E et al. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Haematol 2005; 129: 811–817.

    Article  Google Scholar 

  20. Gonsalves A, Carrier M, Wells PS, McDiarmid SA, Huebsch LB, Allan DS . Incidence of symptomatic venous thromboembolism following hematopoietic stem cell transplantation. J Thromb Haemost 2008; 6: 1468–1473.

    Article  CAS  Google Scholar 

  21. Pihusch R, Salat C, Schmidt E, Gohring P, Pihusch M, Hiller E et al. Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients. Transplantation 2002; 74: 1303–1309.

    Article  Google Scholar 

  22. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W . Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347: 1143–1150.

    Article  CAS  Google Scholar 

  23. Cheong K, Perry D, Karapetis C, Koczwara B . High rate of complications associated with peripherally inserted central venous catheters in patients with solid tumours. Intern Med J 2004; 34: 234–238.

    Article  CAS  Google Scholar 

  24. Tran H, Arellano M, Chamsuddin A, Flowers C, Heffner LT, Langston A et al. Deep venous thromboses in patients with hematological malignancies after peripherally inserted central venous catheters. Leuk Lymphoma 2010; 51: 1473–1477.

    Article  Google Scholar 

  25. Leim TK, Yanit KE, Moseley SE, Landry GJ, DeLoughery TG, Rumwell CR et al. Peripherally inserted central catheter usage patterns and associated upper extremity venous thrombosis. J Vasc Surg (in press).

  26. Lechner D, Wiener C, Weltermann A, Eischer L, Eichinger S, Kyrle PA . Comparison between idiopathic deep vein thrombosis of the upper and lower extremity regarding risk factors and recurrence. J Thromb Haemost 2008; 6: 1269–1274.

    Article  CAS  Google Scholar 

  27. Chaukiyal P, Nautiyal A, Radhakrishnan S, Singh S, Navaneethan SD . Thromboprophylaxis in cancer patients with central venous catheters. A systematic review and meta-analysis. Thromb Haemost 2008; 99: 38–43.

    Article  CAS  Google Scholar 

  28. Jones MA, Lee DY, Segall JA, Landry GJ, Liem TK, Mitchell EL et al. Characterizing resolution of catheter-associated upper extremity deep venous thrombosis. J Vasc Surg 2010; 51: 108–113.

    Article  Google Scholar 

  29. Kovacs MJ, Kahn SR, Rodger M, Anderson DR, Andreou R, Mangel JE et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost 2007; 5: 1650–1653.

    Article  CAS  Google Scholar 

  30. Kanda Y, Yamamoto R, Chizuka A, Suguro M, Hamaki T, Matsuyama T et al. Treatment of deep vein thrombosis using temporary vena caval filters after allogeneic bone marrow transplantation. Leuk Lymphoma 2000; 38: 429–433.

    Article  CAS  Google Scholar 

  31. Stein PD, Hull RD, Raskob GE . Withholding treatment in patients with acute pulmonary embolism who have a high risk of bleeding and negative serial noninvasive leg tests. Am J Med 2000; 109: 301–306.

    Article  CAS  Google Scholar 

  32. Sarkiss MG, Yusuf SW, Warneke CL, Botz G, Lakkis N, Hirch-Ginsburg C et al. Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer 2007; 109: 621–627.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Medical Oncology, Department of Medicine, Oregon Health Sciences University, Portland, OR, USA

    T G DeLoughery

  2. Division of Laboratory Medicine, Department of Pathology, Oregon Health Sciences University, Portland, OR, USA

    T G DeLoughery

Authors
  1. T G DeLoughery
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T G DeLoughery.

Ethics declarations

Competing interests

The author declares no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

DeLoughery, T. Between Scylla and Charybdis: antithrombotic therapy in hematopoietic progenitor cell transplant patients. Bone Marrow Transplant 47, 1269–1273 (2012). https://doi.org/10.1038/bmt.2011.177

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.177

Keywords

Search

Advanced search

Quick links